October 13, 2016
The Japan unit of Merck Serono said on October 12 that it has started enrolling patients in Japan for a PII clinical study for its c-Met kinase inhibitor tepotinib (development code: MSC2156119J) for the treatment adenocarcinoma of the lung. The...read more